Novartis falls to year low on hepatitis trial halt

(Reuters) - "The shares are coming under pressure after the Idenix report," one trader said.




Shares were also pressured after an experimental cancer drug developed with Antisoma Plc failed in a mid-stage clinical trial for ovarian cancer, which was announced Wednesday, and profit taking ahead of second-quarter results due next week, traders said.


Read more at Reuters.com Hot Stocks News